Results 131 to 140 of about 11,461 (257)

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Fabrizio Martora,1 Claudio Marasca,2 Sara Cacciapuoti,1 Federica Fariello,1 Luca Potestio,1 Teresa Battista,1 Massimiliano Scalvenzi,1 Matteo Megna1 1Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II ...
Cacciapuoti S, Battista T, Marasca C, Fariello F, Megna M, Scalvenzi M, Potestio L, Martora F   +7 more
core  

Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab

Pediatric Dermatology, EarlyView.
ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake, Harman Toor, Marie‐Christine Jean, Collin C. Barker, Joseph M. Lam   +4 more
wiley   +1 more source

Surgical approach to extensive hidradenitis suppurativa

, 2021
PURPOSE: Verneuil's disease or perianal hidradenitis suppurativa (HS) is a chronic suppurative disease with a tendency to sinus formation, fibrosis and sclerosis.
Bulut, T, Bugra, D, Akyuz, A, Buyukuncu, Y, Yamaner, S, Balik, E, Sokucu, N   +6 more
core  

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?

Clinical and Experimental Gastroenterology, 2020
Rodrigo Fedatto Beraldo,1 Mariana Barros Marcondes,1 Julio Pinheiro Baima,1 Jaqueline Ribeiro Barros,1 Madhoor Ramdeen,2 Rogerio Saad-Hossne,3 Ligia Yukie Sassaki1 1Department of Internal Medicine, São Paulo State University (Unesp), Medical ...
Beraldo RF, Marcondes MB, Baima JP, Barros JR, Ramdeen M, Saad-Hossne R, Sassaki LY   +6 more
doaj  

Adaptation of the International Consortium for Health Outcomes Measurement Standard Set for Inflammatory Bowel Disease for Routine Collection in Clinical Practice

JCC Plus, Volume 1, Issue 4, July 2026.
ABSTRACT Background and Aims Value‐based healthcare (VBHC) is based on evaluating clinical interventions according to their ability to improve outcomes and costs to finally enhance quality of care. As part of an initiative to introduce VBHC in inflammatory bowel disease (IBD), our project aimed to adapt the International Consortium for Health Outcomes ...
Xavier Calvet, Iago Rodríguez‐Lago, Jose‐Lázaro Pérez‐Calle, Hugo Bronchalo‐Bautista, Elena Barbazán‐García, on behalf of the EEImprove Collaborative Project TEam, Alberto Vegas‐Miguel, Alicia Diaz‐Redondo, Ane Fullaondo‐Zabala, Carles Illa, Celia Albaladejo Blanco, Daniel Ceballos, Ignacio Marín‐Jiménez, Jesus Barrio Andres, Jesús Gonzalo Gómez Gómez, Jone Ortiz de Zaarate Sagastagoitia, Juan Manuel Sánchez Lledó, Laura Gómez‐Irwin, Luis Alberto Menchen Viso, Maite Zabala Ugarteburu, María Carme Nicolás Herrerías, María Dolores Martín‐Arranza, María Esteve Comas, María Mercedes Ortiz Otero, Mirari San Felix Carrasco, Mónica Sierra‐Ausin, Monsterrat Aceituno Quintanilla, Olga Merino Ochoa, Pilar López Serrano, Raúl Martín Puentes, San José Fernando Bermejo, Susana Castelo Zas, Susana Lorenzo Martínez, Yamile Zabana   +33 more
wiley   +1 more source

Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa

, 2011
Hidradenitis suppurativa is a debilitating chronic disease primarily affecting intertriginous skin of the axillae, perineum, and inframammary regions. The pathogenesis of this inflammatory disease is still poorly understood. Recently, increased attention
Nikhil Yawalkar, Schlapbach, Christoph, Hänni, Tanja, Christoph Schlapbach, Robert E. Hunger, Yawalkar, Nikhil, Hunger, Robert E, Tanja Hänni   +7 more
core   +1 more source

Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report

SAGE Open Medical Case Reports
Hidradenitis suppurativa is a chronic inflammatory disease of the skin with a suppurative-cicatricial outcome affecting the infundibular component of the pilo-sebaceous unit.
Paolo Gisondi, Elena Montalto, Tea Curic, Elisabetta Danese, Francesco Bellinato, Giampiero Girolomoni   +5 more
doaj   +1 more source

Skin Tape Stripping: A Non‐Invasive Approach Linking Epidermal Changes and Systemic Inflammation in Atopic Dermatitis

Clinical and Translational Allergy, Volume 16, Issue 6, June 2026.
This review positions skin tape stripping as a methodological bridge in atopic dermatitis, linking epidermal molecular profiling with systemic inflammation. Integrated with multi‐omics technologies, STS enables non‐invasive biomarker discovery, disease endotyping, and treatment monitoring, advancing precision medicine for AD. ABSTRACT Atopic dermatitis
Ziyuan Tian, Ke Xue, Yong Cui
wiley   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Efficacy of Ritlecitinib for Vitiligo Treatment Stratified by Baseline Demographic and Clinical Characteristics: Post Hoc Analysis of a Phase 2b Study

JEADV Clinical Practice, Volume 5, Issue 2, Page 571-576, June 2026.
This post hoc analysis examined the efficacy of ritlecitinib in subgroups of patients with vitiligo, defined by demographic and clinical characteristics. Patients completed the dose‐ranging and extension periods of the phase 2b study (NCT03715829) of ritlecitinib.
A. G. Pandya, I. Hamzavi, P. Ghosh, K. Ezzedine, J. E. Harris, R. Adiri, S. Chen, E. Peeva, Y. Yamaguchi   +8 more
wiley   +1 more source